U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06856681) titled 'Clinical Utility of Early Vs. Late Blood Biomarker Testing for Alzheimer's Disease' on Feb. 06.
Brief Summary: The goal of this study is to evaluate whether use of the PrecivityAD2 blood biomarker assay with early result disclosure along with discretionary Precivity-ApoE proteotype testing will shorten the time to Alzheimer's Disease or non-Alzheimer's diagnosis as compared to delayed result disclosure.
Participants will be randomized into the early PrecivityAD2 blood biomarker test & disclosure group (Cohort A) or to the later PrecivityAD2 blood biomarker test & disclosure group (Cohort B) where blood samples will be collected and...